What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subject receives ZT-01 15 mg by subcutaneous injection daily for 28 days”In the company’s words, NCT05762107 on ClinicalTrials.gov
- Tested for
- Type 1 Diabetes Mellitus With Hypoglycemia
- Main trialPhase 2
- “The goal of this clinical trial is to learn about the effect of the study drug (ZT-01) on low blood sugar (hypoglycemia) in adults with type 1 diabetes (T1D) who have been having low blood sugars ("hypos") at night. ZT-01 increases the amount of a hormone called glucagon during low blood sugar, and this may help prevent the occurrence of hypos. The main questions this trial aims to answer are whether ZT-01 lowers the number of hypos happening at night, and what its effects are on blood sugar levels. The safety of ZT-01 will also be measured. Participants will be asked to wear a…”In the company’s words, NCT05762107 on ClinicalTrials.gov
Coming up1
- DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Dec 2026 | A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | |
| Phase 1Terminated | 12 Apr 2022 | Effect of ZT-01 on Glucagon During Hypoglycemia in Type 1 Diabetes Mellitus |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026